SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-16-528013
Filing Date
2016-04-01
Accepted
2016-04-01 16:42:06
Documents
2
Group Members
VIVO VENTURES FUND VI, L.P.VIVO VENTURES VI AFFILIATES FUND, L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13D d172959dsc13d.htm SC 13D 66131
2 EX-99.A d172959dex99a.htm EX-99.A 7129
  Complete submission text file 0001193125-16-528013.txt   74956
Mailing Address 350 CAMBRIDGE AVE SUITE 350 PALO ALTO CA 94306
Business Address 350 CAMBRIDGE AVE SUITE 350 PALO ALTO CA 94306 650-272-6138
Eiger BioPharmaceuticals, Inc. (Subject) CIK: 0001305253 (see all company filings)

IRS No.: 330971591 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-87931 | Film No.: 161547770
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 575 HIGH STREET, SUITE 201 PALO ALTO CA 94301
Business Address 575 HIGH STREET, SUITE 201 PALO ALTO CA 94301 (650) 688-0818
Vivo Ventures VI, LLC (Filed by) CIK: 0001469547 (see all company filings)

IRS No.: 208829402 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D